Evaluation of toxicity of carmustine with or without bevacizumab in patients with recurrent or progressive high grade gliomas

被引：0
|
作者：
Prakirthi Yerram
Samantha N. Reiss
Lisa Modelevsky
Igor T. Gavrilovic
Thomas Kaley
机构：
[1] Memorial Sloan Kettering Cancer Center,Department of Pharmacy
[2] Memorial Sloan Kettering Cancer Center,Department of Neurology
来源：
Journal of Neuro-Oncology | 2019年 / 145卷
关键词：
High grade glioma; Carmustine; BCNU; Nitrosurea; Bevacizumab; Glioblastoma;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：57 / 63
页数：6
相关论文
共 50 条
  • [1] Evaluation of toxicity of carmustine with or without bevacizumab in patients with recurrent or progressive high grade gliomas
    Yerram, Prakirthi
    Reiss, Samantha N.
    Modelevsky, Lisa
    Gavrilovic, Igor T.
    Kaley, Thomas
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2019, 145 (01) : 57 - 63
  • [2] TOXICITY OF SINGLE AGENT CARMUSTINE VERSUS CARMUSTINE PLUS BEVACIZUMAB IN PATIENTS WITH RECURRENT OR PROGRESSIVE HIGH GRADE GLIOMAS
    Yerram, Prakirthi
    Reiss, Samantha
    Modelevsky, Lisa
    Gavrilovic, Igor
    Kaley, Thomas
    [J]. NEURO-ONCOLOGY, 2017, 19 : 21 - 21
  • [3] Bevacizumab for patients with recurrent high grade gliomas
    Gilbert, Mark R.
    [J]. CANCER INVESTIGATION, 2007, 25 : 1 - 1
  • [4] Re-irradiation with and without bevacizumab as salvage therapy for recurrent or progressive high-grade gliomas
    Hundsberger, Thomas
    Bruegge, Detlef
    Putora, Paul M.
    Weder, Patrik
    Weber, Johannes
    Plasswilm, Ludwig
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2013, 112 (01) : 133 - 139
  • [5] Re-irradiation with and without bevacizumab as salvage therapy for recurrent or progressive high-grade gliomas
    Thomas Hundsberger
    Detlef Brügge
    Paul M. Putora
    Patrik Weder
    Johannes Weber
    Ludwig Plasswilm
    [J]. Journal of Neuro-Oncology, 2013, 112 : 133 - 139
  • [6] RE-IRRADIATION WITH AND WITHOUT BEVACIZUMAB IN RECURRENT OR PROGRESSIVE HIGH-GRADE GLIOMAS (HGG): RETROSPECTIVE ANALYSIS OF 13 PATIENTS
    Hundsberger, T.
    Bruegge, D.
    Weder, P.
    Weber, J.
    Plasswilm, L.
    [J]. NEURO-ONCOLOGY, 2012, 14 : 88 - 88
  • [7] BEVACIZUMAB FOR RECURRENT HIGH-GRADE GLIOMAS
    Sahebjam, Solmaz
    Garoufalis, Evgenia
    Guiot, Marie Christine
    Muanza, Thierry
    Del Maestro, Ronaldo
    Kavan, Petr
    [J]. NEURO-ONCOLOGY, 2010, 12 : 43 - 43
  • [8] BEVACIZUMAB AND FOTEMUSTINE FOR RECURRENT HIGH GRADE GLIOMAS
    Sponghini, A. P.
    Platini, F.
    Rondonotti, D.
    Trevisan, E.
    Soffietti, R.
    [J]. ANNALS OF ONCOLOGY, 2014, 25
  • [9] TREATMENT OF CHILDREN WITH RECURRENT OR PROGRESSIVE HIGH-GRADE GLIOMAS WITH IRINOTECAN, TEMOZOLOMIDE, AND BEVACIZUMAB
    Parekh, Chintan
    Jubran, Rima
    Finlay, Jonathan
    Dhall, Girish
    [J]. NEURO-ONCOLOGY, 2008, 10 (05) : 834 - 834
  • [10] Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas
    Fine, HA
    Wen, PY
    Maher, EA
    Viscosi, E
    Batchelor, T
    Lakhani, N
    Figg, WD
    Purow, BW
    Borkowf, CB
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) : 2299 - 2304
12345